aTyr Pharma, Inc.
LIFE$803M
Small CapNASDAQBiotechnology🇺🇸North America548 employees
Drugs in Pipeline
4
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Apr 15, 2026
4wMarket Overview
Stock performance and key metrics
LIFE News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
Efzofitimod 3 mg/kg
Pulmonary Sarcoidosis
ATYR1940
Limb-Girdle Muscular Dystrophies
efzofitimod 450 mg
Interstitial Lung Disease
Efzofitimod 1 mg/kg
SARS-CoV-2 (COVID-19) Severe Pneumonia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Efzofitimod 3 mg/kg | Phase 3 | Pulmonary Sarcoidosis | - | - |
ATYR1940 | Phase 2 | Limb-Girdle Muscular Dystrophies | - | - |
efzofitimod 450 mg | Phase 2 | Interstitial Lung Disease | - | - |
Efzofitimod 1 mg/kg | Phase 2 | SARS-CoV-2 (COVID-19) Severe Pneumonia | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply